Clinical Trials Browser

Completed × Cognitive Dysfunction × Docosahexaenoic Acids × Clear all

NCT02517502 2022-01-24

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Phase EARLY_PHASE1 Completed

Breast Neoplasms, Cognitive Dysfunction